You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsradipine
Accession NumberDB00270  (APRD00298)
TypeSmall Molecule
GroupsApproved
DescriptionIsradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.
Structure
Thumb
Synonyms
Dynacirc
Isradipino
Isradipinum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IsradipineCapsule5 mg/1OralGolden State Medical Supply, Inc.2015-05-06Not applicableUs
IsradipineCapsule2.5 mg/1OralActavis Pharma, Inc.2004-01-05Not applicableUs
IsradipineCapsule2.5 mg/1OralAv Pak2014-01-06Not applicableUs
IsradipineCapsule5 mg/1OralCarilion Materials Management2006-01-05Not applicableUs
IsradipineCapsule5 mg/1OralActavis Pharma, Inc.2006-01-05Not applicableUs
IsradipineCapsule5 mg/1OralAv Pak2014-01-06Not applicableUs
IsradipineCapsule2.5 mg/1OralEpic Pharma, LLC2014-05-15Not applicableUs
IsradipineCapsule2.5 mg/1OralGolden State Medical Supply, Inc.2015-05-06Not applicableUs
IsradipineCapsule5 mg/1OralEpic Pharma, LLC2014-05-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ClivotenItalfarmaco (Italy)
DynaCircNovartis (Hong Kong, Malaysia, Mexico, New Zealand, South Africa, Singapore, Thailand, Turkey, United States)
Dynacirc CRReliant, GlaxoSmithKline
EsradinSigma-Tau (Italy)
LomirNovartis (Austria, Brazil, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Netherlands, Norway, Poland, Russia, Sweden), Sankyo (Belgium, Italy), Daiichi Sankyo (Portugal, Switzerland), Mizar (Spain)
PrescalNovartis (United Kingdom)
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIYO1UK1S598
CAS number75695-93-1
WeightAverage: 371.3871
Monoisotopic: 371.148120797
Chemical FormulaC19H21N3O5
InChI KeyHMJIYCCIJYRONP-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
IUPAC Name
3-methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C
Pharmacology
IndicationFor the management of mild to moderate essential hypertension. It may be used alone or concurrently with thiazide-type diuretics.
Structured Indications
PharmacodynamicsIsradipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of isradipine result in an overall decrease in blood pressure.
Mechanism of actionIsradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction. Similar to other DHP CCBs, isradipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives isradipine additional arterial selectivity. At therapeutic sub-toxic concentrations, isradipine has little effect on cardiac myocytes and conduction cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1CProteinyes
inhibitor
HumanQ13936 details
Voltage-dependent calcium channel subunit alpha-2/delta-1Proteinyes
inhibitor
HumanP54289 details
Voltage-dependent L-type calcium channel subunit beta-2Proteinyes
inhibitor
HumanQ08289 details
Voltage-dependent T-type calcium channel subunit alpha-1HProteinyes
inhibitor
HumanO95180 details
Voltage-dependent calcium channel subunit alpha-2/delta-2Proteinyes
inhibitor
HumanQ9NY47 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinyes
inhibitor
HumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinyes
inhibitor
HumanQ13698 details
Related Articles
AbsorptionIsradipine is 90%-95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15%-24%.
Volume of distributionNot Available
Protein binding95%
Metabolism

Hepatic. Completely metabolized prior to excretion and no unchanged drug is detected in the urine.

Route of eliminationApproximately 60% to 65% of an administered dose is excreted in the urine and 25% to 30% in the feces.
Half life8 hours
ClearanceNot Available
ToxicitySymptoms of overdose include lethargy, sinus tachycardia, and transient hypotension. Significant lethality was observed in mice given oral doses of over 200 mg/kg and rabbits given about 50 mg/kg of isradipine. Rats tolerated doses of over 2000 mg/kg without effects on survival.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Isradipine Action PathwayDrug actionSMP00378
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Isradipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Isradipine.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Isradipine.Experimental
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Isradipine.Approved
AcebutololThe risk or severity of adverse effects can be increased when Isradipine is combined with Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Isradipine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Isradipine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Isradipine is combined with Acetazolamide.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Isradipine.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Isradipine.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Isradipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isradipine.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Isradipine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Isradipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Isradipine is combined with Aliskiren.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Isradipine.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Isradipine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Isradipine.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Isradipine.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Isradipine.Approved, Illicit, Investigational
AlprenololIsradipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Isradipine.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Isradipine.Approved
AmifostineIsradipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Isradipine is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Isradipine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Isradipine.Approved
AmiodaroneThe metabolism of Isradipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Isradipine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Isradipine.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Isradipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isradipine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Isradipine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Isradipine is combined with Amyl Nitrite.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Isradipine.Investigational
AnagrelideIsradipine may increase the QTc-prolonging activities of Anagrelide.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Isradipine.Approved, Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Isradipine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Isradipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Isradipine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Isradipine is combined with Apraclonidine.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Isradipine.Approved, Investigational
AprepitantThe serum concentration of Isradipine can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Isradipine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Isradipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Isradipine is combined with Arotinolol.Approved
Arsenic trioxideIsradipine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherIsradipine may increase the QTc-prolonging activities of Artemether.Approved
AsenapineIsradipine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Isradipine.Approved, Withdrawn
AtazanavirThe metabolism of Isradipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Isradipine is combined with Atenolol.Approved
AtomoxetineThe metabolism of Isradipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Isradipine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Isradipine is combined with Atosiban.Approved
Atracurium besylateIsradipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Isradipine.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Isradipine.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Isradipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Isradipine is combined with Azilsartan medoxomil.Approved
AzithromycinIsradipine may increase the QTc-prolonging activities of Azithromycin.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Isradipine.Experimental
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Isradipine.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Isradipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Isradipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Barnidipine.Approved
BedaquilineIsradipine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Isradipine is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Isradipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Isradipine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Isradipine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Isradipine.Approved
BepridilIsradipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isradipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Isradipine.Approved
BexaroteneThe serum concentration of Isradipine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Isradipine.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Isradipine.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Isradipine.Approved
BimatoprostIsradipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Isradipine is combined with Bisoprolol.Approved
BoceprevirThe metabolism of Isradipine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Isradipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Isradipine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Isradipine.Approved
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Isradipine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Isradipine is combined with Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Isradipine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Isradipine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Isradipine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Isradipine.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Isradipine.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Isradipine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Isradipine.Approved
BucindololBucindolol may increase the hypotensive activities of Isradipine.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Isradipine.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Isradipine.Approved
BumetanideThe risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Isradipine.Approved, Investigational
BupranololIsradipine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Isradipine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Isradipine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Isradipine.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Isradipine.Approved, Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Isradipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Isradipine.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Isradipine.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Isradipine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Isradipine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Isradipine.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Isradipine.Approved, Nutraceutical
CalciumThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Isradipine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Isradipine is combined with Candesartan.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Isradipine.Withdrawn
CandoxatrilIsradipine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Captopril.Approved
CarbamazepineThe metabolism of Isradipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Isradipine is combined with Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Isradipine.Approved
CarbomycinThe metabolism of Isradipine can be decreased when combined with Carbomycin.Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Isradipine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Isradipine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Isradipine is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Isradipine is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Isradipine.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Isradipine.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Isradipine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Isradipine.Approved, Vet Approved
CeritinibThe serum concentration of Isradipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Isradipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Isradipine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Isradipine.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Isradipine.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Isradipine.Approved, Illicit
ChloroquineIsradipine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Isradipine is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Isradipine.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Isradipine.Approved
ChlorpromazineIsradipine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Isradipine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Isradipine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Isradipine.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Isradipine.Approved, Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Isradipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Isradipine.Approved
CimetidineThe serum concentration of Isradipine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Isradipine.Approved
CiprofloxacinIsradipine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideIsradipine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramIsradipine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Isradipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Isradipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clevidipine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Isradipine.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Isradipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clofarabine.Approved, Investigational
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Isradipine.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Isradipine.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Isradipine.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Isradipine.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Isradipine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Isradipine.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Isradipine.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Isradipine.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Isradipine.Approved, Vet Approved
ClozapineIsradipine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe metabolism of Isradipine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Isradipine.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Isradipine.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Isradipine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Isradipine.Approved
ConivaptanThe serum concentration of Isradipine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Isradipine.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Isradipine.Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Isradipine.Approved
CrizotinibIsradipine may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineIsradipine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Isradipine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Isradipine.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Isradipine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Isradipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideIsradipine may increase the hypotensive activities of Cyclothiazide.Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Isradipine.Approved, Investigational
DabrafenibThe serum concentration of Isradipine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Isradipine.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Isradipine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Isradipine is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Isradipine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Isradipine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Isradipine.Approved, Investigational
DarunavirThe metabolism of Isradipine can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Isradipine.Approved
DasatinibThe serum concentration of Isradipine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Isradipine.Approved
DebrisoquinIsradipine may increase the hypotensive activities of Debrisoquin.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Isradipine.Experimental
DeferasiroxThe serum concentration of Isradipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Isradipine.Approved
DeserpidineIsradipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Isradipine is combined with Desflurane.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Isradipine.Approved
DexamethasoneThe serum concentration of Isradipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Isradipine.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Isradipine.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Isradipine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Isradipine.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Isradipine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Isradipine is combined with Diclofenamide.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Isradipine.Approved
DigoxinThe metabolism of Digoxin can be decreased when combined with Isradipine.Approved
DihydralazineIsradipine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Isradipine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Isradipine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Isradipine is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Isradipine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Isradipine is combined with Dipyridamole.Approved
DisopyramideIsradipine may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Isradipine.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Isradipine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Isradipine.Approved
DolasetronIsradipine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Isradipine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Isradipine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Isradipine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Isradipine is combined with Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Isradipine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Isradipine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Isradipine.Approved, Investigational
DoxycyclineThe metabolism of Isradipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Isradipine.Approved, Illicit
DronedaroneIsradipine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolIsradipine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineIsradipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Isradipine.Approved, Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Isradipine.Approved
EfavirenzThe serum concentration of Isradipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Isradipine.Approved
EfonidipineIsradipine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Isradipine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Isradipine.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Isradipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Isradipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Enalapril.Approved, Vet Approved
EnalaprilatIsradipine may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Isradipine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Isradipine.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Isradipine.Approved
EpoprostenolIsradipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Isradipine is combined with Eprosartan.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Isradipine.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Isradipine.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Isradipine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Isradipine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Isradipine.Approved, Investigational
ErythromycinThe metabolism of Isradipine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramIsradipine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Isradipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Isradipine.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Isradipine.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Isradipine.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Isradipine.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Isradipine.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Isradipine.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Isradipine.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Isradipine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Isradipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Isradipine.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Isradipine.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Isradipine.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Isradipine.Approved, Illicit
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Isradipine.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Isradipine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Isradipine.Approved, Investigational
EtravirineThe serum concentration of Isradipine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Isradipine.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Isradipine.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Isradipine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Isradipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Felodipine.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Isradipine.Approved
FenoldopamIsradipine may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Isradipine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Isradipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Isradipine is combined with Fimasartan.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Isradipine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Isradipine.Approved, Investigational
FlecainideIsradipine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Isradipine.Approved
FluconazoleThe serum concentration of Isradipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Isradipine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Isradipine.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Isradipine.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Isradipine.Approved
FluoxetineIsradipine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolIsradipine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Isradipine.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Isradipine.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Isradipine.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Isradipine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Isradipine.Approved
FluvoxamineThe metabolism of Isradipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Isradipine.Approved
FosaprepitantThe serum concentration of Isradipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Isradipine.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Isradipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Isradipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Isradipine can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidIsradipine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Isradipine.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Isradipine.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Isradipine.Approved
GemifloxacinIsradipine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlipizideThe metabolism of Glipizide can be decreased when combined with Isradipine.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Isradipine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Isradipine.Experimental
GoserelinIsradipine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronIsradipine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Isradipine.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Isradipine.Approved, Vet Approved
GuanabenzIsradipine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Isradipine.Approved
GuanethidineIsradipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Isradipine is combined with Guanfacine.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Isradipine.Approved
HaloperidolIsradipine may increase the QTc-prolonging activities of Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Isradipine.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Isradipine.Approved, Vet Approved
HexamethoniumIsradipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Isradipine.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Isradipine.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Isradipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Isradipine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Isradipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Isradipine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Isradipine.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Isradipine.Approved, Vet Approved
HydroflumethiazideIsradipine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Isradipine.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Isradipine.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Isradipine.Approved
IbutilideIsradipine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Isradipine can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Isradipine resulting in a loss in efficacy.Approved
IloperidoneIsradipine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Isradipine.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Isradipine.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Isradipine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Isradipine.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Isradipine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Isradipine is combined with Indapamide.Approved
IndenololIsradipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Isradipine can be decreased when combined with Indinavir.Approved
IndoraminIsradipine may increase the hypotensive activities of Indoramin.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Isradipine.Approved
IproclozideIproclozide may increase the hypotensive activities of Isradipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Isradipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Isradipine is combined with Irbesartan.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Isradipine.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Isradipine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Isradipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Isradipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isradipine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isradipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isradipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isradipine is combined with Isoxsuprine.Approved, Withdrawn
ItraconazoleThe metabolism of Isradipine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Isradipine.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Isradipine.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Isradipine.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Isradipine.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Isradipine.Approved
JosamycinThe metabolism of Isradipine can be decreased when combined with Josamycin.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Isradipine.Approved, Vet Approved
KetanserinIsradipine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe metabolism of Ketazolam can be decreased when combined with Isradipine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Isradipine.Approved
KetoconazoleThe metabolism of Isradipine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Isradipine can be decreased when combined with Kitasamycin.Experimental
LabetalolThe risk or severity of adverse effects can be increased when Isradipine is combined with Labetalol.Approved
LacidipineIsradipine may increase the hypotensive activities of Lacidipine.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Isradipine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Isradipine.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Isradipine.Investigational
LatanoprostIsradipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LenvatinibIsradipine may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Isradipine.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Isradipine.Approved, Investigational
LeuprolideIsradipine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Isradipine is combined with Levobunolol.Approved
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Isradipine.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Isradipine.Approved
LevodopaIsradipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinIsradipine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Isradipine.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Isradipine.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Isradipine.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Isradipine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Isradipine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Isradipine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Isradipine.Approved
LofexidineIsradipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Isradipine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Isradipine.Approved
LopinavirThe metabolism of Isradipine can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Isradipine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Isradipine.Approved
LosartanThe risk or severity of adverse effects can be increased when Isradipine is combined with Losartan.Approved
LovastatinThe metabolism of Isradipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Isradipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Isradipine can be increased when combined with Lumacaftor.Approved
LumefantrineIsradipine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Isradipine.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Isradipine.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineIsradipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Isradipine is combined with Mannitol.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Isradipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Isradipine.Withdrawn
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Isradipine.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Isradipine is combined with Mecamylamine.Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Isradipine.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Isradipine.Approved
MelatoninMelatonin may decrease the antihypertensive activities of Isradipine.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Isradipine.Approved, Vet Approved
MethadoneIsradipine may increase the QTc-prolonging activities of Methadone.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Isradipine.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Isradipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Isradipine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Isradipine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Isradipine.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isradipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Isradipine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Isradipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Isradipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Isradipine.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Isradipine.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Isradipine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Isradipine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Isradipine is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isradipine.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Isradipine.Approved
MetyrosineIsradipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Isradipine.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Isradipine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Isradipine.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Isradipine.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Isradipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Isradipine.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Isradipine.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Isradipine.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Isradipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Isradipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Isradipine is combined with Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Isradipine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Isradipine.Approved
MitotaneThe serum concentration of Isradipine can be decreased when it is combined with Mitotane.Approved
MivacuriumIsradipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Isradipine.Approved
ModafinilThe serum concentration of Isradipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Isradipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Isradipine.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Isradipine.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Isradipine.Approved, Investigational
MoxifloxacinIsradipine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineIsradipine may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Isradipine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Isradipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Isradipine is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Isradipine is combined with Nadolol.Approved
NafcillinThe metabolism of Isradipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Isradipine.Approved
NaftopidilIsradipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Isradipine.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Isradipine.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Isradipine.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Isradipine.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Isradipine is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Isradipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Isradipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Isradipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Isradipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Isradipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Isradipine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Isradipine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Isradipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nifedipine.Approved
NiguldipineIsradipine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibIsradipine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Isradipine.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Isradipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nisoldipine.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Isradipine.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Isradipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Isradipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Isradipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideIsradipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Isradipine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Isradipine.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Isradipine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Isradipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Isradipine.Approved, Vet Approved
ObinutuzumabIsradipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Isradipine.Withdrawn
OfloxacinIsradipine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Isradipine.Approved
OleandomycinThe metabolism of Isradipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Isradipine is combined with Olmesartan.Approved, Investigational
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Isradipine.Approved
OmapatrilatIsradipine may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Isradipine.Approved, Investigational, Vet Approved
OndansetronIsradipine may increase the QTc-prolonging activities of Ondansetron.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Isradipine.Approved
OsimertinibThe serum concentration of Isradipine can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Isradipine.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Isradipine.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Isradipine.Approved
OxprenololIsradipine may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Isradipine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Isradipine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Isradipine.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Isradipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Isradipine.Investigational
PalbociclibThe serum concentration of Isradipine can be increased when it is combined with Palbociclib.Approved
PaliperidoneIsradipine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Isradipine.Approved, Investigational
PanobinostatIsradipine may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Isradipine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Isradipine is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Isradipine.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Isradipine.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Isradipine.Approved
PargylinePargyline may increase the hypotensive activities of Isradipine.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Isradipine.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Isradipine.Approved
PazopanibIsradipine may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololThe risk or severity of adverse effects can be increased when Isradipine is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Isradipine.Approved
PentobarbitalThe metabolism of Isradipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumIsradipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Isradipine.Approved, Investigational
PerampanelThe metabolism of Perampanel can be decreased when combined with Isradipine.Approved
PerflutrenIsradipine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Isradipine.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Isradipine.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Isradipine.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Isradipine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Isradipine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Isradipine.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Isradipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Isradipine.Withdrawn
PhenobarbitalThe metabolism of Isradipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Isradipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Isradipine.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Isradipine.Approved
PhentolamineIsradipine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Isradipine.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Isradipine.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Isradipine.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Isradipine.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Isradipine.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Isradipine is combined with Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Isradipine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Isradipine is combined with Pipamperone.Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Isradipine.Approved
PirlindolePirlindole may increase the hypotensive activities of Isradipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Isradipine.Withdrawn
PodofiloxThe metabolism of Podofilox can be decreased when combined with Isradipine.Approved
PolythiazideIsradipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Isradipine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Isradipine.Approved
PosaconazoleThe metabolism of Isradipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Isradipine is combined with Pramipexole.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Isradipine.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Isradipine.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Isradipine.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Isradipine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Isradipine.Approved, Vet Approved
PrazosinThe risk or severity of adverse effects can be increased when Isradipine is combined with Prazosin.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Isradipine.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Isradipine.Approved, Vet Approved
PrimaquineIsradipine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Isradipine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideIsradipine may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Isradipine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Isradipine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Isradipine.Approved
PromazineIsradipine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Isradipine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Isradipine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Isradipine is combined with Propranolol.Approved, Investigational
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Isradipine.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Isradipine.Approved, Illicit
QuetiapineIsradipine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Isradipine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Isradipine.Approved
QuinineIsradipine may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Isradipine.Approved, Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Isradipine.Experimental
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Isradipine.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Isradipine.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Isradipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Isradipine.Approved, Investigational
RapacuroniumIsradipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Isradipine.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Isradipine.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Isradipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Isradipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Isradipine.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Isradipine.Approved, Investigational
RescinnamineIsradipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Isradipine.Approved
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Isradipine.Approved
RifabutinThe metabolism of Isradipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Isradipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Isradipine can be increased when combined with Rifapentine.Approved
RilmenidineIsradipine may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Isradipine.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Isradipine.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Isradipine is combined with Riociguat.Approved
RisperidoneIsradipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Isradipine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabIsradipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Isradipine.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Isradipine.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Isradipine.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Isradipine.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Isradipine.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Isradipine.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Isradipine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Isradipine.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Isradipine.Approved, Withdrawn
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Isradipine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Isradipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Isradipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Isradipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Isradipine.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Isradipine.Approved
SaprisartanIsradipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Isradipine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Isradipine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Isradipine.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Isradipine.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Isradipine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Isradipine.Approved, Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Isradipine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Isradipine.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Isradipine.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Isradipine.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Isradipine.Approved, Illicit, Investigational, Withdrawn
SildenafilSildenafil may increase the antihypertensive activities of Isradipine.Approved, Investigational
SilodosinThe metabolism of Silodosin can be decreased when combined with Isradipine.Approved
SiltuximabThe serum concentration of Isradipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Isradipine.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Isradipine.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Isradipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Isradipine.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Isradipine.Approved, Investigational
SitaxentanIsradipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Isradipine is combined with Sodium Nitrite.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Isradipine.Approved
SolithromycinThe metabolism of Isradipine can be decreased when combined with Solithromycin.Investigational
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Isradipine.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Isradipine.Approved, Investigational
SotalolIsradipine may increase the QTc-prolonging activities of Sotalol.Approved
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Isradipine.Approved
SpiraprilIsradipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Isradipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Isradipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Isradipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Isradipine is combined with Streptokinase.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Isradipine.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Isradipine.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Isradipine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Isradipine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Isradipine.Approved
SulfisoxazoleIsradipine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Isradipine.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Isradipine.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Isradipine.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Isradipine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Isradipine.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Isradipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Isradipine.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Isradipine.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Isradipine.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Isradipine.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Isradipine.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Isradipine.Approved
TelaprevirThe metabolism of Isradipine can be decreased when combined with Telaprevir.Approved
TelavancinIsradipine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Isradipine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Isradipine is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Isradipine.Approved
TemocaprilIsradipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Isradipine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Isradipine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Isradipine is combined with Terazosin.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Isradipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Isradipine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Isradipine.Withdrawn
TerlipressinIsradipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Isradipine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Isradipine.Approved, Investigational
TetrabenazineIsradipine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Isradipine.Approved, Vet Approved
ThalidomideThe risk or severity of adverse effects can be increased when Isradipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Isradipine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Isradipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Isradipine.Approved, Vet Approved
ThioridazineIsradipine may increase the QTc-prolonging activities of Thioridazine.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Isradipine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Isradipine.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Isradipine.Approved
TiboloneIsradipine may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Isradipine.Approved
TiclopidineThe metabolism of Isradipine can be decreased when combined with Ticlopidine.Approved
TicrynafenIsradipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Isradipine is combined with Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Isradipine.Approved, Investigational
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Isradipine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Isradipine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Isradipine.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Isradipine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Isradipine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Isradipine.Approved, Investigational
TolazolineIsradipine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Isradipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Isradipine.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Isradipine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Isradipine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Isradipine.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Isradipine.Approved
ToremifeneIsradipine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Isradipine.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Isradipine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Isradipine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Isradipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Isradipine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Isradipine.Approved
TravoprostIsradipine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Isradipine.Approved, Investigational
TreprostinilIsradipine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Isradipine.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Isradipine.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Isradipine is combined with Triamterene.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Isradipine.Approved
TrichlormethiazideIsradipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinIsradipine may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Isradipine.Approved
TrimethaphanIsradipine may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Isradipine.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Isradipine.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Isradipine.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Isradipine.Withdrawn
TroleandomycinThe metabolism of Isradipine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Isradipine can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Isradipine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Isradipine.Approved
UnoprostoneIsradipine may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Isradipine.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Isradipine.Approved, Investigational
VandetanibIsradipine may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Isradipine.Investigational
VardenafilVardenafil may increase the antihypertensive activities of Isradipine.Approved
VemurafenibIsradipine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Isradipine.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Isradipine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Isradipine is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Isradipine.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Isradipine.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Isradipine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Isradipine.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Isradipine.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Isradipine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Isradipine.Approved, Investigational
VinpocetineIsradipine may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Isradipine.Approved
VoriconazoleThe metabolism of Isradipine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Isradipine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Isradipine.Approved
XylometazolineIsradipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Isradipine.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Isradipine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Isradipine.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Isradipine.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Isradipine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Isradipine.Approved, Investigational, Withdrawn
ZiprasidoneIsradipine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Isradipine.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Isradipine.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Isradipine.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Isradipine.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Isradipine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Fletcher H, Roberts G, Mullings A, Forrester T: An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia. J Obstet Gynaecol. 1999 May;19(3):235-8. [PubMed:15512286 ]
  2. Ganz M, Mokabberi R, Sica DA: Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study. J Clin Hypertens (Greenwich). 2005 Apr;7(4 Suppl 1):27-31. [PubMed:15858400 ]
  3. Hattori T, Wang PL: Calcium antagonist isradipine-induced calcium influx through nonselective cation channels in human gingival fibroblasts. Eur J Med Res. 2006 Mar 27;11(3):93-6. [PubMed:16751108 ]
  4. Johnson BA, Roache JD, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y: Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. Int J Neuropsychopharmacol. 2005 Jun;8(2):203-13. [PubMed:15850499 ]
External Links
ATC CodesC08CA03
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier-0.8439
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5855
P-glycoprotein inhibitor IInhibitor0.9322
P-glycoprotein inhibitor IIInhibitor0.8669
Renal organic cation transporterNon-inhibitor0.884
CYP450 2C9 substrateNon-substrate0.8522
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6631
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8557
Ames testNon AMES toxic0.5158
CarcinogenicityNon-carcinogens0.8043
BiodegradationNot ready biodegradable0.9747
Rat acute toxicity2.3960 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8699
hERG inhibition (predictor II)Non-inhibitor0.6895
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Smithkline beecham corp dba glaxosmithkline
  • Actavis totowa llc
  • Watson laboratories inc
  • Glaxosmithkline llc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral2.5 mg/1
CapsuleOral5 mg/1
Prices
Unit descriptionCostUnit
DynaCirc CR 10 mg 24 Hour tablet5.59USD tablet
Dynacirc cr 10 mg tablet4.41USD tablet
DynaCirc CR 5 mg 24 Hour tablet3.0USD tablet
Dynacirc cr 5 mg tablet2.88USD tablet
DynaCirc 5 mg capsule2.31USD capsule
Isradipine 5 mg capsule2.0USD capsule
DynaCirc 2.5 mg capsule1.59USD capsule
Isradipine 2.5 mg capsule1.39USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point168-170 °CNot Available
water solubilityPractically insoluble (< 10 mg/L at 37 °C)Not Available
logP4.28SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.228 mg/mLALOGPS
logP3ALOGPS
logP2ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)5.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area103.55 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity100.08 m3·mol-1ChemAxon
Polarizability37.39 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoxadiazoles. These are organic compounds containing a benzene fused to an oxadiazole ring (a five-membered ring with two carbon atoms, one nitrogen atom, and one oxygen atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxadiazoles
Sub ClassNot Available
Direct ParentBenzoxadiazoles
Alternative Parents
Substituents
  • Dihydropyridinecarboxylic acid derivative
  • Benzoxadiazole
  • Dihydropyridine
  • Benzenoid
  • Hydropyridine
  • Dicarboxylic acid or derivatives
  • Heteroaromatic compound
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Oxadiazole
  • Furazan
  • Azole
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Berjukow S, Marksteiner R, Gapp F, Sinnegger MJ, Hering S: Molecular mechanism of calcium channel block by isradipine. Role of a drug-induced inactivated channel conformation. J Biol Chem. 2000 Jul 21;275(29):22114-20. [PubMed:10766758 ]
  2. Hitzl M, Striessnig J, Neuhuber B, Flucher BE: A mutation in the beta interaction domain of the Ca(2+) channel alpha(1C) subunit reduces the affinity of the (+)-[(3)H]isradipine binding site. FEBS Lett. 2002 Jul 31;524(1-3):188-92. [PubMed:12135765 ]
  3. Zuhlke RD, Bouron A, Soldatov NM, Reuter H: Ca2+ channel sensitivity towards the blocker isradipine is affected by alternative splicing of the human alpha1C subunit gene. FEBS Lett. 1998 May 8;427(2):220-4. [PubMed:9607315 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
Gene Name:
CACNA2D2
Uniprot ID:
Q9NY47
Molecular Weight:
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Koschak A, Reimer D, Huber I, Grabner M, Glossmann H, Engel J, Striessnig J: alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6. Epub 2001 Apr 2. [PubMed:11285265 ]
  2. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23